ArticleJournal of applied clinical medical physics2019
Selection of prescription isodose line for brain metastases treated with volumetric modulated arc radiotherapy.
Article in Journal of applied clinical medical physics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Benchmarking intermediate dose spillage in single target stereotactic radiosurgery for brain metastases.Physics and imaging in radiation oncology · 2026Article
- Stereotactic radiotherapy for metastatic brain tumors: A comparative analysis of dose distributions among VMAT, Helical TomoTherapy, CyberKnife, Gamma Knife, and ZAP-X.Journal of applied clinical medical physics · 2025Article
- What is the optimal isodose line for stereotactic radiotherapy for single brain metastases using HyperArc?Journal of applied clinical medical physics · 2024Article
- The dosimetric parameters impact on local recurrence in stereotactic radiotherapy for brain metastases.The British journal of radiology · 2024Article
- Comparison of dosimetric parameters and robustness for rotational errors in fractionated stereotactic irradiation using automated noncoplanar volumetric modulated arc therapy for patients with brain metastases: single- versus multi-isocentric technique.Radiological physics and technology · 2023Article
- An analytical expression for R50% dependent on PTV surface area and volume: A cranial SRS comparison.Journal of applied clinical medical physics · 2021Article
- Critically ill patients with cancer: A clinical perspective.World journal of clinical oncology · 2020Review
- Spatially fractionated radiotherapy (SFRT) targeting the hypoxic tumor segment for the intentional induction of non-targeted effects: AnTechnical innovations & patient support in radiation oncology · 2020Article
- Evaluation of Normal Tissue Objective Function for Treatment Planning of Solitary Brain Metastasis Using Intensity-modulated Radiosurgery Techniques.Journal of medical physicsArticle
- Effects of Institutional Experience on Plan Quality in Stereotactic Radiotherapy Using HyperArc for Brain Metastases.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
purposeTo exploit the optimal prescription isodose line (IDL) for brain metastases treated with volumetric modulated arc radiotherapy (VMAT) as there is no consensus on the selection of IDL with VMAT. METHODS AND MATERIALS: Eighteen patients with 20 brain tumors, who were treated with VMAT, were enrolled in this study. For each tumor of every patient, five plans were designed with IDL ranging from 50% to 90% in 10% increments. Different IDLs were obtained through adjusting the constraint parameters during planning optimization. Prescription dose (10 × 5 Gy) were identical for all plans, and the plans were compared in terms of gradient index (GI), conformity Index (CI), V26 Gy/V
resultsIDL with lowest GI has a median value of 60.0% (ranging from 50% to 80%). Except for one tumor with volume larger than 10 cc, the IDL with lowest GI varies from 50% to 70%, which depends on the shape of PTV, location, and whether the target volume is adjacent to crucial OAR. Moreover, there is no significant difference for CI with varying IDL plans. The average V26 Gy/V
conclusionsPlans using VMAT with PTV smaller than 10 cc tend to be optimal with IDL around 60-70% for lower GI, smaller V26 Gy/V
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.